Introduction
Radiopharmaceuticals used to be a small, specialized corner of the pharmaceutical industry — mostly diagnostic imaging agents with a handful of therapeutic exceptions. That's changed. Radioligand therapies, where a targeting molecule delivers a radioactive isotope directly to cancer cells, have moved from experimental to commercially approved treatments across several tumor types, and the pipeline behind them is large. That growth has created real hiring demand for regulatory affairs professionals who understand this product class, and the pool of people with that experience is genuinely small. This article looks at what makes radiopharmaceutical regulatory work distinct, why the talent gap exists, what the roles actually look like day to day, and what it takes to move into this niche.
What makes radiopharmaceuticals regulatory work different
A radiopharmaceutical is regulated as a drug — through the standard NDA, ANDA, or BLA pathways in the US, and analogous frameworks elsewhere — but it carries an added layer of complexity that a conventional small molecule or biologic doesn't. The product itself is radioactive, which means radiation safety, dosimetry, and short shelf-life logistics all become regulatory considerations, not just manufacturing ones. Many radiopharmaceuticals have half-lives measured in hours, which means the product must be manufactured, released, and administered to a patient within a tight window — sometimes at a facility close to or co-located with the treating hospital. Regulatory submissions for these products have to address chemistry and manufacturing controls for both the radioactive and non-radioactive components, along with dosimetry studies that estimate radiation exposure to the patient's organs. None of this is covered in a typical regulatory affairs training path, which is exactly why experience in the space is scarce. Even labeling looks different: radiopharmaceutical labels typically need to communicate handling and disposal precautions that a conventional drug label never has to address.
Two distinct product families: diagnostic and therapeutic
It's worth separating two categories that get lumped together under "radiopharmaceuticals" but present different regulatory challenges. Diagnostic radiopharmaceuticals — imaging agents used with PET or SPECT scanners — have a long regulatory history and relatively established review pathways, though the manufacturing and distribution logistics remain demanding. Therapeutic radiopharmaceuticals, including radioligand therapies that deliver a cytotoxic radiation dose directly to tumor cells, are newer as a commercial category and involve additional regulatory considerations around therapeutic dosimetry, patient-specific dosing in some cases, and long-term safety follow-up given the cumulative radiation exposure involved. A regulatory professional moving into this niche should understand which side of that line a given role sits on, since the day-to-day work and the relevant precedent differ meaningfully between the two.
Overlap with radiation safety and nuclear regulatory frameworks
In the United States, radiopharmaceutical manufacturing and distribution intersect with oversight from the Nuclear Regulatory Commission and state radiation control programs, in addition to FDA review of the drug itself. A regulatory affairs professional working in this space doesn't need to be a health physicist, but does need enough fluency in radiation safety concepts to coordinate effectively with the specialists who are — and to understand how radioactive materials licensing affects manufacturing site selection, distribution logistics, and even how a clinical trial protocol gets designed. This cross-disciplinary coordination is one of the more distinctive parts of the job, and it's a skill set that doesn't show up in most regulatory affairs job descriptions outside this niche. It also means regulatory affairs professionals in this space end up working more closely with supply chain and manufacturing teams than is typical elsewhere, since a short half-life product can't simply be stockpiled or shipped on a standard commercial timeline.
Why the talent pool is thin
Radiopharmaceuticals were a quiet corner of nuclear medicine for decades, mostly diagnostic imaging agents like technetium-based scans, with a small and stable community of specialists. The recent wave of radioligand therapy approvals and the resulting investment surge happened faster than the specialist talent pool could grow to match it. Companies building out radiopharmaceutical pipelines are now competing for a relatively small number of regulatory professionals who have hands-on experience with dosimetry submissions, radioactive drug manufacturing controls, and the logistics of short-half-life products — and that scarcity shows up in how aggressively these roles are recruited and, often, in compensation. It also shows up in how long some of these roles stay open; hiring managers in this space frequently describe struggling to find candidates who check every box, which has pushed some companies toward hiring strong generalists and investing in training instead of waiting for a perfect-fit specialist.
How people move into this niche
Few people start their career in radiopharmaceutical regulatory affairs; most arrive from an adjacent path. Common routes in include general oncology or nuclear medicine regulatory experience, a background in CMC regulatory work with exposure to sterile or short-shelf-life products, or prior experience in a hospital nuclear medicine or radiopharmacy setting before moving into industry. Some companies are willing to hire strong generalist CMC or regulatory affairs candidates and train them on the radiopharmaceutical-specific pieces, particularly as the hiring need has outpaced the specialist supply — which makes this a niche worth watching even for people without direct experience yet. Professional development resources are still catching up too; there is no single widely recognized certification specific to radiopharmaceutical regulatory affairs, so most of the specialized knowledge in this field is still learned on the job or through targeted conference sessions and working groups within organizations like RAPS or DIA.
What the roles actually look like
Job titles in this space vary — regulatory affairs CMC specialist, radiopharmaceutical regulatory lead, or simply regulatory affairs manager within a company whose entire portfolio is radioligand therapies. What they have in common is a heavier-than-usual emphasis on manufacturing and quality coordination, close collaboration with radiation safety and supply chain functions, and submissions that read differently from a standard small-molecule package because of the added dosimetry and radiation exposure sections. Understanding this before you interview for one of these roles will help you ask sharper questions and gauge whether the day-to-day work matches what you're picturing. It's also worth asking, during an interview, how the company's manufacturing and distribution network is structured — centralized versus regional production has a real effect on how much of the regulatory workload involves site-specific licensing and distribution logistics versus core submission strategy.
What this means for compensation and negotiation
Scarce, specialized experience tends to translate into leverage for candidates, and radiopharmaceutical regulatory affairs is no exception. Candidates with direct dosimetry submission experience or prior radioactive drug manufacturing exposure are in a genuinely strong negotiating position right now, simply because so few people can speak credibly to that experience in an interview. For candidates without direct experience but with strong adjacent CMC or oncology regulatory backgrounds, it's worth being upfront in interviews about what you don't yet know and asking what onboarding or mentorship the company offers to close that gap — companies investing in this space are often realistic about training needs, since the alternative is leaving a role unfilled for months.
Where this hiring activity is concentrated
Radiopharmaceutical manufacturing has real geographic logic behind it, driven by the need to keep short-half-life products close to the patients who receive them and, in many cases, close to the cyclotrons or reactors that produce the relevant isotopes. That means hiring for these roles tends to cluster around companies that have built or are building dedicated radiopharmaceutical manufacturing networks, as well as around academic medical centers and specialized contract manufacturing organizations that already have nuclear medicine infrastructure in place. For a regulatory professional evaluating a move into this niche, it's worth researching a given company's manufacturing footprint specifically, since a company relying on a single centralized site faces different regulatory and supply chain questions than one building out a distributed regional network.
Questions worth asking before you commit to this niche
Beyond the standard interview questions, candidates evaluating a radiopharmaceutical regulatory role should ask what stage the company's pipeline is at — a preclinical or early-clinical program presents very different regulatory work than a company managing an approved commercial product and its post-approval commitments. It's also worth asking directly how the company sources its isotopes and whether that supply chain has historically been stable, since isotope availability has a real and sometimes underappreciated effect on regulatory and manufacturing planning in this space. Finally, ask what the internal collaboration looks like between regulatory affairs and the radiation safety or health physics function — a well-integrated relationship between those groups is usually a sign of a mature program, while a disconnected one can mean regulatory affairs is regularly caught off guard by issues that radiation safety saw coming.
Conclusion
Radiopharmaceuticals have gone from a niche corner of nuclear medicine to a genuine growth area in oncology drug development, and the regulatory affairs talent market hasn't fully caught up to that shift. For regulatory professionals with CMC, oncology, or nuclear medicine adjacent experience, it's a niche worth exploring — both because the work is technically interesting and because the hiring demand, for now, exceeds the available supply of experienced candidates.